Cargando…
Should personalised dosing have a role in cancer treatment?
Almost all pharmaceutical products are approved on the basis of their effect in patients representing the “average” of the population studied in registrational trials, with most drug labels allowing, at most, for empirical dose reduction in the case of toxicity. In this perspective article we explor...
Autores principales: | Villette, Claire C., Orrell, David, Millen, Jim, Chassagnole, Christophe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196464/ https://www.ncbi.nlm.nih.gov/pubmed/37213297 http://dx.doi.org/10.3389/fonc.2023.1154493 |
Ejemplares similares
-
Editorial: Personalised multimodal prehabilitation in cancer
por: West, MA., et al.
Publicado: (2022) -
Personalised treatment for cancer: role of biomarkers
por: Duffy, Michael J
Publicado: (2014) -
Editorial: Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine
por: Melosky, Barbara
Publicado: (2017) -
Is personalised prehabilitation feasible to implement for patients undergoing oncological treatment for lung cancer at a London teaching hospital? Protocol of a feasibility trial
por: Wade-Mcbane, Kelly, et al.
Publicado: (2023) -
Personalised treatment for older adults with cancer: The role of frailty assessment
por: O'Donovan, Anita, et al.
Publicado: (2020)